Platinum Investment Management Ltd. Has $1.75 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Platinum Investment Management Ltd. increased its stake in Arrowhead Pharmaceuticals by 12.8%, now holding approximately 0.08% of the company, valued at $1.75 million.
• Insider James C. Hamilton sold 15,000 shares at an average price of $30.00, reflecting a 6.07% decrease in his position, alongside a total of 40,000 shares sold by insiders in the last quarter.
• Arrowhead Pharmaceuticals has a consensus rating of "Buy" from analysts, with target prices ranging from $60.00 to $80.00, and recently reported a loss of $1.26 EPS against a consensus estimate of $0.94.

Platinum Investment Management Ltd. increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,022 shares of the biotechnology company's stock after purchasing an additional 12,613 shares during the period. Platinum Investment Management Ltd. owned approximately 0.08% of Arrowhead Pharmaceuticals worth $1,754,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ARWR. Mackenzie Financial Corp acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter worth $137,000. GAMMA Investing LLC boosted its stake in Arrowhead Pharmaceuticals by 4,965.8% in the 1st quarter. GAMMA Investing LLC now owns 27,710 shares of the biotechnology company's stock worth $3,530,000 after purchasing an additional 27,163 shares during the period. Yousif Capital Management LLC boosted its stake in Arrowhead Pharmaceuticals by 5.2% in the 1st quarter. Yousif Capital Management LLC now owns 47,347 shares of the biotechnology company's stock worth $603,000 after purchasing an additional 2,353 shares during the period. SG Americas Securities LLC acquired a new position in Arrowhead Pharmaceuticals in the 1st quarter worth $871,000. Finally, Pinion Investment Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 100.0% in the 1st quarter. Pinion Investment Advisors LLC now owns 150,000 shares of the biotechnology company's stock worth $1,911,000 after purchasing an additional 75,000 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider James C. Hamilton sold 15,000 shares of the company's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the transaction, the insider owned 232,122 shares in the company, valued at approximately $6,963,660. This represents a 6.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 40,000 shares of company stock valued at $1,025,000. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on ARWR. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Chardan Capital reissued a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Up 1.5%

Shares of ARWR stock opened at $35.01 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The firm's 50-day moving average is $23.76 and its 200-day moving average is $17.89. The stock has a market cap of $4.84 billion, a price-to-earnings ratio of -27.35 and a beta of 1.12. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $35.40.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the firm posted ($1.38) earnings per share. Sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.